Exagen (XGN) Q4 2025 earnings review
Volume Grows, But Missed Profitability Target and Decelerating Guidance Raise Red Flags
Exagen delivered a 20% full-year revenue increase fueled by >11% AVISE CTD volume growth, but the Q4 results contradict management's previous bullish narrative. Throughout 2025, leadership repeatedly guided to achieving positive adjusted EBITDA in Q4. This target was entirely missed, with Q4 Adjusted EBITDA deteriorating to -$3.67M. Gross margins compressed sharply, and the critical Average Selling Price (ASP) expansion stalled. Adding to the concern, FY26 revenue guidance implies a severe deceleration to mid-single-digit growth, suggesting that payer pushback on new biomarkers is materially impairing the company's turnaround timeline.
🐂 Bull Case
AVISE CTD test volume grew over 11% in FY25, reaching 137,000 tests. The expanded sales force is successfully driving clinical adoption and market penetration, proving the fundamental demand for the product.
Following a Q2 equity offering and debt refinancing, Exagen ends the year with $32.4 million in cash and equivalents, providing ample liquidity runway to absorb the current cash burn while management recalibrates its reimbursement strategy.
🐻 Bear Case
Management's credibility took a hit as the highly touted Q4 positive Adjusted EBITDA target resulted in a $3.67M loss—worse than the $2.54M loss a year ago. Operating expenses are rising faster than revenue can compensate.
Trailing twelve-month ASP flatlined at $441 in Q4, identical to Q3, indicating that the anticipated $90 uplift from new RA and T-Cell biomarkers is being neutralized by payer denials and the loss of high-value direct bill accounts.
⚖️ Verdict: 🔴
Bearish. Failing to deliver on a heavily telegraphed profitability target, accompanied by plunging gross margins and decelerating forward guidance, breaks the core investment thesis. Execution on reimbursement is lagging significantly behind clinical innovation.
Key Themes
Severe Reversing Trend in Gross Margin
Gross margin suffered a dramatic compression in Q4, dropping to 55.4% from a peak of 60.4% in 25Q2 and 58.4% in 25Q3. Management previously projected margins expanding into the 'low 60s' in the second half of 2025. This reversal indicates that lab operation investments and sluggish payer collections for the new biomarkers are crushing unit economics.
ASP Expansion Hits a Wall
The entire path to profitability was predicated on driving ASP toward $500. While TTM ASP is up $30 YoY to $441, it has completely stalled sequentially (Q3 was also $441). The initial higher-than-expected payer denials for the new anti-PAD4 and T-cell markers, combined with the Q3 loss of a major direct bill account, have derailed the pricing momentum.
Comprehensive RA Panel Strengthens Value Proposition
Despite reimbursement struggles, the clinical strategy is working. The commercial launch of novel T-Cell and seronegative RA biomarkers (anti-RA33 and anti-PAD4) has increased the panel's sensitivity for Rheumatoid Arthritis to roughly 85% (vs. ~70% for conventional tests). This compelling clinical utility is the primary driver behind the 11% FY25 volume growth.
Operating Leverage is Reversing
The company failed to scale its expenses relative to revenue. Q4 operating expenses jumped to $14.18M. With gross profits at $9.2M in Q4, the company generated an operating loss of nearly $5.0M. Management's investments in the sales force and R&D are outpacing the cash collected per test, creating a widening structural deficit.
Other KPIs
Accelerating YoY (+21.8% vs 24Q4), but decelerating sequentially from Q3's $17.24M. The sequential dip is highly concerning given the ongoing sales force expansion and previously touted lack of typical seasonality.
A significant deterioration from the -$15.11 million net loss in 2024. Increased interest expenses from the new credit facility and rising SG&A costs outstripped the 20% topline growth.
Stable. Up from $22.0 million at the end of 2024, fortified by a $20 million equity offering and debt restructuring executed earlier in the year. This liquidity is critical given the delayed timeline to positive cash flow.
Guidance
Decelerating. The midpoint of $71.5M implies just 7.4% year-over-year growth, representing a massive slowdown from the 19.6% growth achieved in FY25. This suggests management is capitulating on near-term ASP expansion and signaling that payer pushback will suppress revenue growth for the foreseeable future.
Key Questions
The Q4 Profitability Miss
Management consistently guided to positive adjusted EBITDA in Q4, yet delivered a $3.67M loss. What specific assumptions in your Q3 forecasting broke down so severely in the span of just 90 days?
Gross Margin Collapse
Gross margins plunged to 55.4% in Q4 after trending near 60% earlier in the year. How much of this was driven by pricing pressure versus increased unit lab costs, and what is the realistic run-rate for FY26?
Decelerating FY26 Guidance
Your FY26 revenue guidance implies ~7% growth, down from nearly 20% in FY25. Is this deceleration purely a function of zero assumed ASP expansion, or are you also projecting a material slowdown in AVISE CTD volume growth?
Payer Denial Progress
Given the stalled ASP, what concrete metrics can you share regarding the success rate of your appeals process for the new anti-PAD4 and T-cell markers over the last 90 days?